Focus Partners Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Focus Partners Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.59M	Sell	4,802 -2,281	-32%	-$776K	﹤0.01%	1419
2025 Q4	$2.82M	Buy	7,083 +466	+7%	+$206K	﹤0.01%	1184
2025 Q3	$2.99M	Buy	6,617 +3,467	+110%	+$1.41M	﹤0.01%	900
2025 Q2	$1.03M	Sell	3,150 -1,068	-25%	-$296K	﹤0.01%	1131
2025 Q1	$1.14M	Sell	4,218 -209	-5%	-$53.7K	﹤0.01%	1019
2024 Q4	$1.04M	Buy	4,427 +3,144	+245%	+$827K	﹤0.01%	1047
2024 Q3	$353K	Sell	1,283 -210	-14%	-$54.7K	﹤0.01%	1274
2024 Q2	$363K	Buy	+1,493	New	+$236K	﹤0.01%	1020

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Focus Partners Wealth's ALNY Position: Q1 2026 in Review

Focus Partners Wealth reduced its Alnylam Pharmaceuticals (ALNY) stake by 32% in Q1 2026, selling an estimated $776K and leaving 4,802 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Focus Partners Wealth first reported a position in ALNY in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.99M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Focus Partners Wealth held 4,802 shares of Alnylam Pharmaceuticals worth $1.59M as of Q1 2026.
Focus Partners Wealth sold 2,281 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $776K.
Alnylam Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #1419 holding.
Focus Partners Wealth first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Focus Partners Wealth's Alnylam Pharmaceuticals position peaked at $2.99M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.